Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Malignant Melanoma

  Free Subscription


2 Ann Surg Oncol
1 BMC Ophthalmol
2 Br J Dermatol
1 Clin Exp Metastasis
2 J Am Acad Dermatol
1 J Invest Dermatol
4 Melanoma Res
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

  1. SPILLANE AJ, Menzies AM, van Akkooi ACJ
    The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients - A Potential Paradigm Shift in Management.
    Ann Surg Oncol. 2020 May 14. pii: 10.1245/s10434-020-08566.
    PubMed         Abstract available

  2. FARROW NE, Beasley GM
    ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy.
    Ann Surg Oncol. 2020 May 14. pii: 10.1245/s10434-020-08561.

    BMC Ophthalmol

  3. SHAO JW, Yin JH, Xiang ST, He Q, et al
    CT and MRI findings in relapsing primary malignant melanoma of the lacrimal sac: a case report and brief literature review.
    BMC Ophthalmol. 2020;20:191.
    PubMed         Abstract available

    Br J Dermatol

  4. BEHBAHANI S, Malerba S, Samie FH
    Acral Lentiginous Melanoma: Clinicopathologic Characteristics and Survival Outcomes in the United States National Cancer Database 2004 -2016.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19211.
    PubMed         Abstract available

  5. TALAGANIS JA, Gregoriou S, Stratigos AJ
    Stress and melanoma. Myth or reality?
    Br J Dermatol. 2020 May 10. doi: 10.1111/bjd.19035.

    Clin Exp Metastasis

  6. BARBOZA T, Gomes T, da Costa Medeiros P, Ramos IP, et al
    Development of (131)I-ixolaris as a theranostic agent: metastatic melanoma preclinical studies.
    Clin Exp Metastasis. 2020 May 11. pii: 10.1007/s10585-020-10036.
    PubMed         Abstract available

    J Am Acad Dermatol

  7. PRASSINOS A, Glusac E, Leffell DJ
    Melanoma in situ: Don't make the cure worse than the disease.
    J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30825.

  8. MARCHETTI MA, Liopyris K, Navarrete-Dechent C
    Net benefit and decision curve analysis of competing diagnostic strategies for cutaneous melanoma.
    J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30830.

    J Invest Dermatol

  9. NGUYEN MQ, Teh JLF, Purwin TJ, Chervoneva I, et al
    Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition.
    J Invest Dermatol. 2020 May 7. pii: S0022-202X(20)31406.
    PubMed         Abstract available

    Melanoma Res

  10. VERA AGUILERA J, Paludo J, McWilliams RR, Zhang H, et al
    Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000669.
    PubMed         Abstract available

  11. JANELA-LAPERT R, Bouteiller J, Deschamps-Huvier A, Duval-Modeste AB, et al
    Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000665.
    PubMed         Abstract available

  12. DALMASSO C, Pages C, Chaltiel L, Brun A, et al
    Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000670.
    PubMed         Abstract available

  13. CONIC RRZ, Knackstedt R, Sussman TA, Rambhia S, et al
    Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000672.
    PubMed         Abstract available

    PLoS One

  14. Correction: Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.
    PLoS One. 2020;15:e0233424.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.